197 related articles for article (PubMed ID: 27466480)
21. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease.
Rink T; Truong PN; Schroth HJ; Diener J; Zimny M; Grünwald F
Thyroid; 2009 Apr; 19(4):327-32. PubMed ID: 19355822
[TBL] [Abstract][Full Text] [Related]
22. Other markers of medullary thyroid cancer, not only calcitonin.
Censi S; Manso J; Mian C
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
[TBL] [Abstract][Full Text] [Related]
23. Procalcitonin as an Alternative Tumor Marker of Medullary Thyroid Carcinoma.
Giovanella L; Garo ML; Ceriani L; Paone G; Campenni' A; D'Aurizio F
J Clin Endocrinol Metab; 2021 Nov; 106(12):3634-3643. PubMed ID: 34382653
[TBL] [Abstract][Full Text] [Related]
24. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract][Full Text] [Related]
25. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
26. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Aug; 99(8):2986-94. PubMed ID: 24840813
[TBL] [Abstract][Full Text] [Related]
27. Can procalcitonin be useful for medullary thyroid cancer?
Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
[TBL] [Abstract][Full Text] [Related]
28. Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment.
Fugazzola L; Di Stefano M; Censi S; Repaci A; Colombo C; Grimaldi F; Magri F; Pagotto U; Iacobone M; Persani L; Mian C
J Endocrinol Invest; 2021 Mar; 44(3):587-597. PubMed ID: 32656666
[TBL] [Abstract][Full Text] [Related]
29. Calcitonin as Biomarker for the Medullary Thyroid Carcinoma.
Bae YJ; Schaab M; Kratzsch J
Recent Results Cancer Res; 2015; 204():117-37. PubMed ID: 26494386
[TBL] [Abstract][Full Text] [Related]
30. Expression of Prox1 in Medullary Thyroid Carcinoma Is Associated with Chromogranin A and Calcitonin Expression and with Ki67 Proliferative Index, but Not with Prognosis.
Saglietti C; La Rosa S; Sykiotis GP; Letovanec I; Bulliard JL; Piana S; Mermod M; Petrova T; Uccella S; Sessa F; Bongiovanni M
Endocr Pathol; 2019 Jun; 30(2):138-145. PubMed ID: 31001799
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
32. Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis.
Trimboli P; Giannelli J; Marques B; Piccardo A; Crescenzi A; Deandrea M
Endocrine; 2022 Jan; 75(1):33-39. PubMed ID: 34606057
[TBL] [Abstract][Full Text] [Related]
33. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
34. Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).
Grande E; Santamaría Sandi J; Capdevila J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Gómez Sáez JM; Jiménez-Fonseca P; Riesco-Eizaguirre G; Galofré JC
Clin Transl Oncol; 2016 Aug; 18(8):769-75. PubMed ID: 26687366
[TBL] [Abstract][Full Text] [Related]
35. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
Elisei R; Bottici V; Luchetti F; Di Coscio G; Romei C; Grasso L; Miccoli P; Iacconi P; Basolo F; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2004 Jan; 89(1):163-8. PubMed ID: 14715844
[TBL] [Abstract][Full Text] [Related]
36. Novel acquisitions in the diagnosis of medullary thyroid carcinoma.
Trimboli P; Crescenzi A; Saggiorato E; Treglia G; Giovanella L
Minerva Endocrinol; 2017 Sep; 42(3):238-247. PubMed ID: 27808486
[TBL] [Abstract][Full Text] [Related]
37. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
[TBL] [Abstract][Full Text] [Related]
38. Histopathology of C Cells and Medullary Thyroid Carcinoma.
Schmid KW
Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
[TBL] [Abstract][Full Text] [Related]
40. Renal calcitonin amyloidosis in a patient with disseminated medullary thyroid carcinoma.
Tan Y; Li DY; Ma TT; Xu R; Zhou FD; Wang SX; Zhao MH
Amyloid; 2020 Sep; 27(3):213-214. PubMed ID: 32425063
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
